Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Stunning new James Webb Space Telescope images reveal 'hidden' stars being born - 2CDC clarifies stance on vaccines and autism, stating no evidence supports the link
- 3The 1st full moon of 2026 rises tonight! Here's what to expect from January's supermoon Wolf Moon
- 4Rick Steves Prefers Paying A Bit Extra For This Delectable Food When Dining In Spain
- 5The most effective method to Begin Your Excursion in Gold Venture
- Jupiter and the moon take a sunset stroll on March 26. Here's how to see it
- Israeli archaeologists launch project to trace origins of ancient pottery
- Rebecca Gayheart on her 'very complicated' relationship with Eric Dane: 'I am always going to want the best for him'
- Polls open in tense Uganda election amid widespread delays
- Italian authorities detain civilian rescue ship, German NGO says
- 2 ways you can conserve the water used to make your food
- The Artemis II launch is tonight. Here's how to watch it live.
- Web designers for Independent ventures
- RSF attack on Sudan’s South Kordofan kills at least 14, including children
